− HEALTH We are the last generation that will influence what wellbeing means before AI systems optimize that definitio…− HEALTH Abstract There is much discussion of the false outputs that generative AI systems such as ChatGPT, Claude, Ge…± SCIENCE This article presents a Delphi consensus developed by a panel of editors-in-chief of anaesthesiology and pain…+ EDUCATION The study investigated how innovative, AI-supported teaching methods relate to the mathematics problem-solvin…+ EDUCATION As generative AI becomes increasingly integrated into higher education, understanding how students engage wit…+ HEALTH In the complex and multidimensional field of medicine, multimodal data are prevalent and crucial for informed…± SCIENCE This paper explores the evolution of geoscientific inquiry, tracing the progression from traditional physics-…− POLICY This paper conducts a systematic review and interdisciplinary analysis of the ethical challenges of generativ…
TruaceTracing the truth around AIMonday, July 20, 2026
Subscribe
Health·The Trace·Model-prefilled trace·Published 2026-07-20

prediction of metastasis after prostatectomy using MMAI

Source article: Combining pathology artificial intelligence and genomic biomarkers to refine long-term postprostatectomy outcome prediction

BACKGROUND: A multimodal AI (MMAI) model has been validated in prostate biopsy specimens to guide treatment intensification in men receiving radiation. The MMAI has been explored to an extent for prostatectomy patients and has not yet been examined in relation to established genomic scores. METHODS: We applied the MMAI biopsy model to a tissue microarray (TMA) of 424 prostatectomy cases with long-term follow-up. MMAI scores were derived from digitized pathology images and clinical variables. Associations with bi…

TRV-2026-0324Peer-reviewedPermanent record — cite & verify
Trace impact reading

Negative state: both sides are scored from claims and sources, not community votes.

P 73The P score combines the specificity and measured human impact of the grounded problem claim with the strength of this Trace’s cited sources.G 68The G score combines the specificity and measured human impact of the grounded gain claim with the strength of this Trace’s cited sources.
Combining pathology artificial intelligence and genomic biomarkers to refine long-term postprostatectomy outcome prediction

"Partial Hydatidiform Mole" by euthman is licensed under CC BY 2.0. To view a copy of this license, visit https://creativecommons.org/licenses/by/2.0/.

The quick read

By July 2026, investigators had tested a multimodal AI model originally validated in prostate biopsy specimens on a tissue microarray of 424 prostatectomy cases, generating scores for 414 patients. At 10 years, recurrence-free survival was 74% and metastasis-free survival 96%, and MMAI scores were associated with both endpoints in univariable models.

The finding matters because it suggests pathology AI developed for biopsies can provide prognostic signal from prostatectomy TMA spots and add complementary information to genomic CCP scores, reaching c-index 0.76 for metastasis. Uncertainty remains because MMAI was not independently prognostic after CAPRA adjustment, did not outperform CAPRA, and was not designed for TMAs, requiring further refinement and validation.

Main points
  • Study applied MMAI biopsy model to a tissue microarray of 424 prostatectomy cases with long-term follow-up, generating scores for 414 patients (98%).
  • At 10 years, recurrence-free and metastasis-free survival were 74% and 96%, respectively.
  • Correlation between MMAI and either CAPRA or CCP was modest (r < 0.35).
  • Combined MMAI and CCP model had c-index 0.76 for metastasis, comparable to CAPRA c-index 0.75.
Gain

In 414 prostatectomy cases, the MMAI score derived from digitized pathology images was associated with long-term biochemical recurrence and metastasis, and when combined with genomic CCP score reached the highest discrimination for metastasis.

Problem

MMAI lost independent prognostic value after adjustment for CAPRA clinical risk score and did not outperform established clinical tools for postprostatectomy outcome prediction.

The rundown

Researchers applied the biopsy-validated MMAI model, using digitized pathology images and clinical variables, to a tissue microarray of prostatectomy cases with long-term follow-up.

In univariable analysis MMAI was associated with BCR and metastasis, remained significant when adjusted for genomic CCP score but not after adjustment for CAPRA, and the MMAI plus CCP combination achieved c-index 0.76 for metastasis.

What this doesn’t fix

Model was originally developed for whole slide biopsy specimens and tested on TMA spots, did not outperform established clinical tools, and authors note need for further refinement and validation in diverse settings.

Sources

Reader signal

How should this claim be treated?

The debate